-
FDA Approves Opdualag-Related Biosimilar: What You Need to Know About Degevma
A New Option for Bone Health The U.S. Food and Drug Administration (FDA) has officially approved Degevma (denosumab-adet), a biosimilar medication designed to serve as an interchangeable option for Xgeva. This approval marks a significant development in the landscape of oncology and bone-health supportive care. Understanding Degevma Degevma is a RANK ligand inhibitor. It is…
-
FDA Approves Garzuly: A New Biosimilar Option for Insulin Aspart
A New Milestone in Diabetes Care The FDA has officially granted approval for Garzuly (insulin aspart), a significant development for patients managing diabetes. As a biosimilar to NovoLog, Garzuly offers an alternative treatment option for individuals requiring insulin aspart to improve glycemic control. What You Need to Know About Garzuly Biosimilars are designed to be…
-
FDA Greenlights FILKRI™: Accord BioPharma Completes Comprehensive G-CSF Portfolio for Oncology Support
Accord BioPharma Secures FDA Approval for FILKRI™ (filgrastim-laha), Biosimilar to NEUPOGEN® Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., has announced a significant milestone: the U.S. Food and Drug Administration (FDA) has approved FILKRI™ (filgrastim-laha). This product is a biosimilar to the established reference product, NEUPOGEN® (filgrastim). The approval, announced on February 17,…